Tags

Type your tag names separated by a space and hit enter

Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group.
Osteoporos Int 1999; 9(4):358-66OI

Abstract

A total of 277 early postmenopausal women were enrolled in this placebo-controlled 2-year study to examine the efficacy of a matrix transdermal 17beta-estradiol system, at three different dosages (25, 50 and 75 mg/day) combined with sequential oral dydrogesterone 20 mg/day, in preventing bone loss. At 2 years, the difference from placebo in percentage change from baseline of L1-4 lumbar spine bone mineral density (BMD) (assessed by dual-energy X-ray absorptiometry) was 4.7% +/- 0.7% with estradiol 25 mg/day, 7.3% +/- 0.7% with estradiol 50 mg/day and 8.7% +/- 0.7% with estradiol 75 mg/day (all values mean +/- SEM). There were also significant increases in femoral neck, trochanter and total hip BMD with all doses of estradiol compared with placebo. Additionally, most patients had a significant gain (increase greater than 2.08%) in lumbar spine bone mass compared with placebo. Patients who received estradiol also experienced clinically significant and dose-related decreases in total serum osteocalcin, serum bone alkaline phosphatase and urinary C-telopeptide, with all three markers of bone turnover returning to premenopausal levels. Estradiol was well tolerated during the 2-year treatment period. Transdermal estradiol is effective and well tolerated at dosages between 25-75 mg/day in the prevention of bone loss in postmenopausal women; 25 mg/day offers an effective option for those women who cannot tolerate higher doses.

Authors+Show Affiliations

Southampton General Hospital, Southampton, UK.

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

10550454

Citation

Cooper, C, et al. "Matrix Delivery Transdermal 17beta-estradiol for the Prevention of Bone Loss in Postmenopausal Women. the International Study Group." Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 9, no. 4, 1999, pp. 358-66.
Cooper C, Stakkestad JA, Radowicki S, et al. Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. Osteoporos Int. 1999;9(4):358-66.
Cooper, C., Stakkestad, J. A., Radowicki, S., Hardy, P., Pilate, C., Dain, M. P., & Delmas, P. D. (1999). Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 9(4), pp. 358-66.
Cooper C, et al. Matrix Delivery Transdermal 17beta-estradiol for the Prevention of Bone Loss in Postmenopausal Women. the International Study Group. Osteoporos Int. 1999;9(4):358-66. PubMed PMID: 10550454.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. AU - Cooper,C, AU - Stakkestad,J A, AU - Radowicki,S, AU - Hardy,P, AU - Pilate,C, AU - Dain,M P, AU - Delmas,P D, PY - 1999/11/7/pubmed PY - 1999/11/7/medline PY - 1999/11/7/entrez SP - 358 EP - 66 JF - Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA JO - Osteoporos Int VL - 9 IS - 4 N2 - A total of 277 early postmenopausal women were enrolled in this placebo-controlled 2-year study to examine the efficacy of a matrix transdermal 17beta-estradiol system, at three different dosages (25, 50 and 75 mg/day) combined with sequential oral dydrogesterone 20 mg/day, in preventing bone loss. At 2 years, the difference from placebo in percentage change from baseline of L1-4 lumbar spine bone mineral density (BMD) (assessed by dual-energy X-ray absorptiometry) was 4.7% +/- 0.7% with estradiol 25 mg/day, 7.3% +/- 0.7% with estradiol 50 mg/day and 8.7% +/- 0.7% with estradiol 75 mg/day (all values mean +/- SEM). There were also significant increases in femoral neck, trochanter and total hip BMD with all doses of estradiol compared with placebo. Additionally, most patients had a significant gain (increase greater than 2.08%) in lumbar spine bone mass compared with placebo. Patients who received estradiol also experienced clinically significant and dose-related decreases in total serum osteocalcin, serum bone alkaline phosphatase and urinary C-telopeptide, with all three markers of bone turnover returning to premenopausal levels. Estradiol was well tolerated during the 2-year treatment period. Transdermal estradiol is effective and well tolerated at dosages between 25-75 mg/day in the prevention of bone loss in postmenopausal women; 25 mg/day offers an effective option for those women who cannot tolerate higher doses. SN - 0937-941X UR - https://www.unboundmedicine.com/medline/citation/10550454/Matrix_delivery_transdermal_17beta_estradiol_for_the_prevention_of_bone_loss_in_postmenopausal_women__The_International_Study_Group_ DB - PRIME DP - Unbound Medicine ER -